ARIDIS PHARMACEUTICALS INC (ARDS) Stock Analyst Earnings Estimates
NASDAQ:ARDS - Nasdaq - US0403341045 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1M -1.96% | 1.54M 54.00% | 3.091M 100.71% | 38.25M 1,137.46% | 42.24M 10.43% | 77.44M 83.33% | 132.77M 71.45% | 201.47M 51.74% | 257.63M 27.88% | |
| EBITDA YoY % growth | -22.06M 23.27% | -42.27M -91.61% | -29.506M 30.20% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -22.4M 23.00% | -42.71M -90.67% | -29.993M 29.78% | -11.511M 61.62% | 7.485M 165.02% | 40.379M 439.47% | 96.61M 139.26% | 164.59M 70.37% | 220.01M 33.67% | |
| Operating Margin | -2,240.00% | -2,773.38% | -970.33% | -30.09% | 17.72% | 52.14% | 72.76% | 81.69% | 85.40% | |
| EPS YoY % growth | -2.44 30.68% | -4.18 -71.31% | -1.96 53.11% | -0.55 71.90% | 0.27 148.15% | 1.50 465.38% | N/A | N/A | N/A |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | -0.60 34.78% | -0.42 | -0.18 | -43.47% |
| Q3 2022 Q2Q % growth | -0.47 75.77% | -0.17 | -0.30 | -171.05% |
| Q2 2022 Q2Q % growth | -0.45 18.18% | -0.06 | -0.39 | -635.29% |
| Q1 2022 Q2Q % growth | -0.44 42.86% | -0.52 | 0.08 | 15.42% |
| Q4 2021 Q2Q % growth | -0.92 -55.93% | -0.42 | -0.50 | -119.99% |
| Q3 2021 Q2Q % growth | -1.94 -198.46% | -0.52 | -1.42 | -270.51% |
| Q2 2021 Q2Q % growth | -0.55 -17.02% | -0.64 | 0.09 | 14.07% |
| Q1 2021 Q2Q % growth | -0.77 -5.48% | -0.63 | -0.14 | -22.25% |
| Q4 2020 Q2Q % growth | -0.59 6.35% | -0.61 | 0.02 | 2.51% |
| Q3 2020 Q2Q % growth | -0.65 25.29% | -0.64 | -0.01 | -1.47% |
| Q2 2020 Q2Q % growth | -0.47 54.37% | -0.76 | 0.29 | 38.07% |
| Q1 2020 Q2Q % growth | -0.73 26.26% | -0.68 | -0.05 | -6.82% |
| Q4 2019 Q2Q % growth | -0.63 | -0.82 | 0.19 | 23.51% |
| Q3 2019 Q2Q % growth | -0.87 | -0.34 | -0.53 | -158.47% |
| Q2 2019 Q2Q % growth | -1.03 | -0.86 | -0.17 | -19.50% |
| Q1 2019 Q2Q % growth | -0.99 | -0.88 | -0.11 | -11.99% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2023 Q2Q % growth | 1.082M -8.85% | % | ||
| Q4 2022 Q2Q % growth | 1.213M 22.90% | 314.497K | 898.503K | 285.70% |
| Q3 2022 Q2Q % growth | 399K -22.52% | 7.616M | -7.217M | -94.76% |
| Q2 2022 Q2Q % growth | 292K 784.85% | 10.672M | -10.38M | -97.26% |
| Q1 2022 Q2Q % growth | 1.187M | 2.04M | -853K | -41.81% |
| Q4 2021 Q2Q % growth | 987K | 1.938M | -951K | -49.07% |
| Q3 2021 Q2Q % growth | 515K | 170.003K | 344.997K | 202.94% |
| Q2 2021 Q2Q % growth | 33K -96.70% | 306K | -273K | -89.22% |
| Q1 2021 Q2Q % growth | 102K | -102K | -100.00% | |
| Q4 2020 Q2Q % growth | 510K | -510K | -100.00% | |
| Q3 2020 Q2Q % growth | 318.75K | -318.75K | -100.00% | |
| Q2 2020 Q2Q % growth | 1M | 275.4K | 724.6K | 263.11% |
| Q1 2020 Q2Q % growth | -100.00% | 318.75K | -318.75K | -100.00% |
| Q4 2019 Q2Q % growth | 892.5K | -892.5K | -100.00% | |
| Q3 2019 Q2Q % growth | 5.746M | -5.746M | -100.00% | |
| Q2 2019 Q2Q % growth | 492.997K | -492.997K | -100.00% | |
| Q1 2019 Q2Q % growth | 1.02M | 739.5K | 280.5K | 37.93% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 33.33% | 33.33% |
| Revenue | N/A | N/A | 47.06% | 47.06% |